Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- CMIC Completes Acquisition of Daiichi Sankyo Propharma's Shizuoka Plant
April 19, 2010
- Q&A on Biosimilars Issued
April 19, 2010
- More than Just the Money
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
April 19, 2010
- Alfresa to Tie Up with 4 Wholesalers
April 19, 2010
- Takeda to Enhance Training of Executives with Global Business Capabilities
April 19, 2010
- JSIM Introduces COI Self-Reporting Requirement from April 12
April 19, 2010
- MCI Provides Tablet PCs to All MRs from Benesis
April 19, 2010
- Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
April 19, 2010
- GSK to Disclose Payments to Physicians Made in 2009 and Onward
April 19, 2010
- 637 Monitors Certified in 2nd JCROA Monitor Certification Test
April 19, 2010
- Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
April 19, 2010
- Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
April 19, 2010
- Taiyo Can No Longer Be Family-Owned Company: President Aratani
April 19, 2010
- AnGes MG to Codevelop NF-κB Decoy with Shionogi
April 19, 2010
- Ajinomoto Pharm. to Enter Southeast Asian Market
April 19, 2010
- DB on Medicinal Plants Posted on NIBIO Website
April 19, 2010
- HPs Have Stronger Resistance to Generics than GPs
April 19, 2010
- Valsartan Delays Progression to Type 2 Diabetes in CV Patients with IGT
April 19, 2010
- Tokyo District Court Rejects Teva's Lawsuit against Kyowa Kirin
April 12, 2010
- Denosumab Prevents SRE in Breast Cancer
April 12, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…